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Palivizumab efﬁciently blocks respiratory syncytial virus (RSV) infection in vitro. However, virus
neutralization assays generally omit Fc region-mediated effects. We investigated the neutralization ac-
tivity of RSV-speciﬁc monoclonal antibodies on cells with Fc receptors. Subneutralizing concentrations of
antibodies resulted in antibody-dependent enhancement of RSV infection in monocytic cells. Contrary to
antibodies targeting other epitopes, the neutralization by palivizumab was augmented in cells with Fc
receptors. This unrecognized characteristic of palivizumab may be relevant for its performance in vivo.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Respiratory syncytial virus (RSV) is the major cause of severe
respiratory infections during infancy (Nair et al., 2010). The only
approved antiviral intervention is palivizumab, a monoclonal, hu-
manized, immunoglobulin G1 (IgG1) directed against the fusion
glycoprotein (F) (Groothuis et al., 1993). Prophylactic administra-
tion of palivizumab to neonates at high-risk for severe RSV infec-
tion reduces hospitalization rates by 50% (Group, 1998). Currently,
novel monoclonal antibodies (mAb) and more than 50 RSV vaccine
candidates are in development (Modjarrad et al., 2015).
Serum antibodies against RSV correlate poorly with probability
of protection in challenge studies and severe RSV infection in ne-
onates can occur despite the presence of maternal antibodies in
serum (Habibi et al., 2015; Eick et al., 2008). Human sera and RSV-
speciﬁc murine monoclonal antibodies can also enhance RSV
infection (Gimenez et al., 1989; Krilov et al., 1989; Gimenez et al.,
1996) by interacting with Fc gamma receptors (FCGR). RSV-
antibody immune complexes also modulate the response of im-
mune cells (Gomez et al., 2016; Jans et al., 2014). Thus, antibodies
may play an ambivalent role during RSV infection, like in dengue
virus infection (van der Schaar et al., 2009).
Novel therapeutic antiviral mAbs are primarily selected for1, 3720BA Bilthoven, The
r B.V. This is an open access articlebetter virus neutralization as compared to palivizumab. This is
assessed by virus neutralization assays in vitro. Antibody-mediated
effector functions such as antibody-dependent cell cytotoxicity,
immunomodulation, and complement activation act beyond
neutralization, but are generally omitted from analysis (Pelegrin
et al., 2015). In the present study we analyzed to what extent the
neutralizing capacity of humanized RSV-speciﬁc monoclonal anti-
bodies in general, and of palivizumab in particular, is affected in
cells with FCGRs. The presence of FCGR generally weakened RSV
neutralization. In contrast, palivizumab showed augmented
neutralization. Additionally, all tested humanized mAbs demon-
strated antibody-dependent enhancement (ADE) of RSV infection
in THP-1 cells, even at very low concentrations.2. RSV infection of THP-1 cells is enhanced by mAbs
The interaction of endogenous FCGRs on murine P388D1 cells
with complexes of RSV and murine mAbs facilitates ADE (Krilov
et al., 1989). We asked whether humanized mAbs, in particular
the therapeutic mAb palivizumab or the next generation, high-
afﬁnity mAb D25, cause ADE. To assess the dilution range where
mAbs cause ADE, a recombinant RSV expressing green ﬂuorescent
protein (E7-rRSV_X (Widjojoatmodjo et al., 2010)), was pre-
incubated with serial diluted mAbs (overview in Table 1), a human
IgG1 isotype control (Mab901, Eureka therapeutics), or puriﬁed,
human, serum-derived immunoglobulin (IVIG, KIOVIG, Baxter) for
1 h at 37 C. THP-1 cells or Vero-E6 cells were inoculated at aunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Characteristics of monoclonal antibodies.
Antibody IVIGb D25c Palivizumabb,c 47Fd 101Fe 131-2Ab 131-
2Gb
3D3f Isotypeb
Species Human Human Human Murine Human Murine Murine Human Human
Fc subclass diverse IgG1 IgG1 IgG1 IgG1 IgG2a IgG1 IgG1 IgG1
Target RSV protein Total RSV F, prefusion F, pre/
postfusion
F, prea/
postfusion
F, pre/
postfusion
F,
postfusion
Gg Gg Unspeciﬁed
Antigenic site in F Polyclonal Ø II II IV I n.a. n.a. n.a.
IC50 in Vero cells (ng/ml) (95% CI) 11,857 (11,010
e12,761)
2.99 (2.79
e3.18)
478 (443e519) 1068 (975
e1176)
37.8 (33.4
e42.5)
n.a. n.a. n.a. n.a.
IC50 in THP-1 cells (ng/ml) (95%
CI)
56,717 (41,147
e80,992)
125 (8.94
e17.26)
179 (139e267) 809 (501e1351) 150 (105e223) n.a. n.a. n.a. n.a.
CI ¼ 95% conﬁdence interval, n.a. Not applicable.
a Predicted.
b Commercial.
c Rigter et al., 2013.
d Garcia-Barreno et al., 1989.
e Produced similarly as described previously for D25 and Palivizumab (Rigter et al., 2013) based on sequences in patent US 20060159695 A1.
f Collarini et al., 2009.
g Binding to central conserved region in RSV-G.
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ques per well, respectively. THP-1 cells display Fc gamma receptor
1a (FCGR1A) and Fc gamma receptor 2a (FCGR2A) on the plasma-
membrane whereas Vero cells lack FCGRs (Fleit and Kobasiuk,
1991). THP-1 cells were infected by spinoculation at 700g for
1 h at room temperature, after which the inoculum was removed,
cells were washed and fresh medium was added. After overnight
incubation, RSV infection was quantiﬁed by assessing GFP-positive
cells using ﬂow cytometry (FACS Canto II, BD). Titration curves were
displayed normalized to samples without antibody (100% infection)
(Fig.1A). Inhibition of RSV infection of Vero cells was determined by
plaque reduction neutralization assays as described earlier (van
Remmerden et al., 2012). In short, RSV-antibody complexes were
spinoculated, followed by 1 h incubation at 37 C. Next, the inoc-
ulumwas replenishedwithmedium containing 1%methylcellulose.
48 h post infection, GFP-positive foci were counted. Similar to IVIG,
all RSV-speciﬁc mAbs increased infection of THP-1 cells to >200% at
sub-neutralizing concentrations (Fig. 1CeK). Treatment of RSV with
various antibodies that do not recognize RSV antigens (data not
shown) as well as isotype control antibody (Fig. 1D) resulted in
similar infection at all tested dilutions. RSV-neutralizing mAbs
blocked infection at high concentrations and enhanced infection at
low concentrations (Fig. 1EeH). For D25, the maximum infection
was observed at a dilution corresponding to a concentration as low
as 1 ng/ml. Therefore, our experiments proved to be an extremely
sensitive tool to detect antibody-FCGR interactions. Non-
neutralizing antibodies 131-2A, 131-2G, and 3D3 increased infec-
tion up to 350% at all tested concentrations until diluted out
(Fig. 1IeK). ADE occurred independent of neutralization titer,
epitope speciﬁcity, species, or any other known attribute of the
antibody (Table 1). To exclude interference by the Fc region sub-
class, all antibodies with human Fc regions were chosen to be of
subclass IgG1 that efﬁciently interacts with FCGR1A and FCGR2a.
Murine IgG2a, present in mAb 131-2A, interacts strongly with hu-
man monocytic Fc receptors, whereas murine IgG1 Fc regions of
47F and 131-2G interact less (Lubeck et al., 1985). However, all
murine Abs sufﬁciently bound human FCGR to cause ADE in THP-
1 cells.
3. RSV neutralization by palivizumab is augmented on THP-
1 cells
Next, we asked how virus neutralization is affected by FCGR
interactions. We expected that ADE mitigates neutralization by
increasing the 50% inhibitory concentration (IC50). IC50s of IVIGand the different mAbs were calculated by non-linear regression
(Graphpad Prism 7). Intriguingly, the IC50 of palivizumab (Medi-
mmune) was lower in THP-1 cells than in Vero cells (Fig. 1B).
Identical results were obtained with in-house produced pal-
ivizumab (Rigter et al., 2013). We could ﬁnd a similar, but weaker
augmentation of neutralization for 47F (Fig. 1H) that also binds to
antigenic site II in RSV F (Garcia-Barreno et al., 1989). In contrast,
other mAbs and IVIG had a higher IC50 in THP-1 cells.
4. RSV neutralization by palivizumab is augmented on Vero
cells with Fc gamma receptors
To gain more insight into the augmented neutralizing capacity
of palivizumab and to exclude cell line-speciﬁc differences, we
developed Vero cells with either of the two FCGR present on THP-
1 cells. FCGR1A has a >10-fold higher afﬁnity for IgG1 and both
FCGRs contain an intracellular immunoreceptor tyrosine-based
activation motif. Vero cells expressing FCGR2A (designated
Vero2a) or co-expressing the murine common gamma chain
(FCER1G) and FCGR1A (designated Vero1a) were generated by
retroviral transduction (Bruhns and Jonsson, 2015). Stable, poly-
clonal cell lines were selected by antibiotics and surface display of
FCGRs was conﬁrmed by ﬂow cytometry (data not shown). Vero1a,
Vero2a, and the parental Vero cells produced similar amounts of
plaques after infection with RSV (data not shown). The presence of
sub-neutralizing mAb concentrations enhanced RSV infection
(Fig. 2AeI) for IVIG, D25, 101F, 131-2A (MAB8599, Millipore), and
131-2G (MAB858-2, Millipore) on Vero1a and IVIG, 131-2A, and
D25 (University Utrecht (Rigter et al., 2013)) on Vero2a. This ADE
was not as pronounced as on THP-1 cells. Furthermore, IC50 values
of neutralizing antibodies were altered in presence of FCGRs as
demonstrated by shifting of the titration curves when using Vero1a
and Vero2a cells instead of Vero cells (Fig. 2J). Palivizumab had a
14.2-fold and 1.7-fold lower IC50 using Vero1a and Vero2a,
respectively (Fig. 2K). Slightly better neutralization was also
observed for 47F using Vero2a (2.6-fold) and D25 in Vero1a (1.3-
fold). All other RSV-speciﬁc antibodies and IVIG required a higher
concentration for neutralization in Vero cells with FCGRs. Shifts of
IC50s in FCGR-bearing Vero cells were statistically signiﬁcant in all
cases (Fig. 2J).
5. Implications of antibody-FCGR interaction
We studied the impact of interactions between FCGRs and hu-
manizedmAb on RSV infection by RSV neutralization assays. Higher
Fig. 1. Neutralization activity of palivizumab was augmented on THP-1 cells compared to Vero cells. Infection of Fc gamma receptor carrying, monocytic THP-1 cells by RSV in
the presence of monoclonal antibodies. (A) Schematic of dose-dependent RSV neutralization normalized to infection in the absence of antibodies. Neutralizing antibodies block RSV
infection at high concentrations. Antibody-dependent enhancement (ADE) of infection can occur at low concentrations or by non-neutralizing antibodies. Furthermore, the half
maximal inhibitory concentration (IC50) is changed when using cells with Fc gamma receptors, illustrated by shifting titration curves. (B) To compare neutralization, IC50 derived
from THP-1 cells was divided by IC50 on Vero cells. Titration curves of human plasma immunoglobulin (IVIG, panel C) and individual antibodies are shown (panels DeK). The RSV
epitope that is recognized by mAbs is indicated. Graphs report means and standard deviations based on 3 independent experiments measured in duplicate or triplicate for THP-1
or Vero cells, respectively.
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RSV when FCGRs are present in target cells. In contrast, the pres-
ence of FCGRs, especially high-afﬁnity receptor FCGR1A, greatlyaugmented the neutralization activity of palivizumab. This previ-
ously unrecognized characteristic of palivizumab should be taken
into account when using palivizumab as a reference standard for
Fig. 2. Neutralization activity of palivizumab is augmented on Vero cells in presence of Fc gamma receptors. IC50 of human plasma immunoglobulin (IVIG, (A)) and
monoclonal antibodies (BeI) were determined in Vero cells and Vero cells that stably express Fc gamma receptor 1a (Vero1a) or Vero cells with Fc gamma receptor 2a (Vero2a). The
RSV epitope that is recognized by mAbs is indicated. Graphs report means and standard deviations based on 3 independent experiments measured in triplicate. (J) Mean IC50
(with 95% conﬁdence interval) of 4 independent experiments were calculated. IC50 on Vero2a and Vero1a are signiﬁcantly different from Vero cells using Dunnett’s test (P < 0.01).
(K) To illustrate the change of IC50 in the presence of FCGRs, logIC50 in Vero1a or Vero2a were compared to that in Vero cells using a two-way ANOVA and plotted with 99%
conﬁdence interval after linear transformation.
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Collarini et al., 2009).
This study elucidates some aspects, but cannot fully compre-
hend how IC50s are modulated by antibody-FCGR interactions. The
F protein antigenic site II that is recognized by palivizumab and 47Fseems to support FCGR-augmented neutralization independent of
the origin of the Fc region and the engaged FCGR. Nevertheless,
direct comparison with other mAbs is challenging, since variable
phenotypes may occur when different in Fc regions are present.
How individual FCGRs operate could not be concluded from this
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Fc-FCGR interactions depend on the immunoglobulin species, (sub-
)class, and modiﬁcations of the N-linked glycan in the Fc region
(Vidarsson et al., 2014).
Besides altering the IC50, FCGRs facilitated antibody-dependent
enhancement of RSV infection (Krilov et al., 1989). For human sera
and murine mAbs, ADE was dependent on the balance between
neutralization and enhancement, whereas non-neutralizing mAbs
generally enhanced infection (Gimenez et al., 1996). We report
similar effects for humanized mAbs that are in clinical use or in
development. ADE even occurs when the mAbs was designed for
high potency, binding to prefusion F epitope Ø, and present at
concentrations as low as 0.1 ng/ml (Fig. 2F). All tested RSV-
neutralizing mAbs could enhance infection of THP-1 cells, hence
we could not address whether ADE was determined of Fc region,
afﬁnity, and neutralization capacity.
Mechanism that causes ADE of RSV infection remains elusive.
(Antibody-mediated) endocytosis may trafﬁc RSV into a favorable
endosomal compartment where proteases unleash the fusion ma-
chinery of RSV to enable viral release in to the cytoplasm
(Krzyzaniak et al., 2013). ADE was generally more pronounced in
Vero1a than Vero2a. This might originate either from the higher
afﬁnity with which FCGR1A binds IgG, relate to the increased
trafﬁcking of FCGR1A-bound immunecomplexes to the late endo-
somal/lysosomal compartment (Dai et al., 2009), and is consistent
with the enhanced uptake of and infection by Dengue virus im-
mune complexes via FCGR1A (Chawla et al., 2013). Augmented
neutralization of RSV, however, is unique to palivizumab in our
study. The generally weak ADE in FCGR-bearing Vero cells may
occur due to cell type speciﬁc differences, incompatibility between
simian Vero cells and human FCGRs, or the lack of synergy between
FCGR1A and FCGR2A.
Antibody-Fc gamma receptor interactions result in altered
neutralization and ADE in vitro. In vivo, FCGR-bearing immune cells
are crucial for the antiviral response. Stimulation of FCGR-
dependent immune responses may contribute to RSV-mediated
pathogenesis (Ponnuraj et al., 2003; Gomez et al., 2016; Kruijsen
et al., 2013). Like in dengue virus infection (van der Schaar et al.,
2009), antibodies may thus play an ambivalent role during RSV
infection. Hence, Fc receptor-mediated effects should be considered
when evaluating novel antibodies and vaccines (Bournazos and
Ravetch, 2015).
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